{
  "_metadata": {
    "version": "2.0",
    "extracted_from": "ARWR Investment Thesis, Company Presentations, FDA Database",
    "extraction_date": "2026-02-05",
    "analyst_reviewed": true
  },
  "asset": {
    "name": "Plozasiran",
    "alternate_names": ["ARO-APOC3", "REDEMPLO"],
    "company": "Arrowhead Pharmaceuticals",
    "ticker": "ARWR",
    "stage": "Approved (FCS) / Phase 3 (sHTG)",
    "modality": "RNAi (siRNA)",
    "ownership": "Partnered with Amgen",
    "one_liner": "First-in-class RNAi therapeutic achieving 80% triglyceride reduction with quarterly dosing"
  },
  "target": {
    "name": "APOC3",
    "full_name": "Apolipoprotein C-III",
    "class": "Lipoprotein metabolism regulator",
    "pathway": "Triglyceride metabolism",
    "biology": {
      "simple_explanation": "APOC3 is a protein that inhibits lipoprotein lipase (LPL), the enzyme that clears triglycerides from the blood. By silencing APOC3 with RNAi, plozasiran unleashes LPL activity, dramatically accelerating clearance of triglyceride-rich lipoproteins.",
      "pathway_detail": "APOC3 inhibits LPL on capillary endothelium, slowing TG-rich lipoprotein catabolism. APOC3 also promotes hepatic VLDL secretion and impairs hepatic uptake of remnant lipoproteins.",
      "downstream_effects": [
        "Increased LPL activity",
        "Accelerated TG-rich lipoprotein clearance",
        "Reduced VLDL secretion",
        "Reduced pancreatitis risk in FCS patients"
      ]
    },
    "why_good_target": {
      "clinical_validation": "Loss-of-function mutations in APOC3 are associated with ~40% lower triglycerides and reduced cardiovascular risk",
      "genetic_validation": {
        "loss_of_function": "APOC3 LoF carriers have lower TG, lower coronary heart disease"
      },
      "source": {
        "id": "arwr_thesis_2026",
        "verified": true
      }
    }
  },
  "mechanism": {
    "type": "RNAi (siRNA) via TRiM platform",
    "delivery": "GalNAc-conjugated for hepatocyte targeting",
    "how_it_works": "Plozasiran is a GalNAc-conjugated siRNA that is taken up specifically by hepatocytes via the asialoglycoprotein receptor. Once inside, it engages the RISC machinery to catalytically degrade APOC3 mRNA, reducing APOC3 protein production by >90%.",
    "catalytic_advantage": "Each siRNA molecule can degrade multiple mRNA transcripts, enabling potent and durable knockdown with quarterly dosing",
    "potency": {
      "apoc3_reduction": ">90%",
      "tg_reduction": "80%"
    },
    "source": {
      "id": "arwr_thesis_2026",
      "verified": true
    }
  },
  "indications": {
    "lead": {
      "name": "Familial Chylomicronemia Syndrome (FCS)",
      "patient_population": "~3,000 US patients",
      "status": "Approved (Nov 2025)",
      "brand_name": "REDEMPLO",
      "rationale": "Ultra-rare orphan disease with no prior approved therapies providing adequate TG reduction"
    },
    "expansion": [
      {
        "name": "Severe Hypertriglyceridemia (sHTG)",
        "patient_population": "~500,000 US patients",
        "status": "Phase 3 (SHASTA-3/4/5)",
        "rationale": "10x larger market than FCS; high unmet need for pancreatitis prevention"
      },
      {
        "name": "Mixed Hyperlipidemia",
        "patient_population": "Millions",
        "status": "Phase 3 (MUIR-3)",
        "rationale": "Combination with statins for residual CV risk"
      }
    ],
    "development_strategy": "FCS approval provides orphan exclusivity and validates mechanism. sHTG represents the larger commercial opportunity.",
    "source": {
      "id": "arwr_thesis_2026",
      "verified": true
    }
  },
  "market_opportunity": {
    "fcs_market": "Orphan indication, ~$500M potential",
    "shtg_market": "~$2-3B potential if trials succeed",
    "competitive_advantage": "Best-in-class TG reduction (80% vs ~60% for olezarsen), favorable safety vs volanesorsen",
    "source": {
      "id": "arwr_thesis_2026",
      "verified": false
    }
  },
  "clinical_data": {
    "palisade_phase3": {
      "trial_name": "PALISADE",
      "nct_id": "NCT05089084",
      "design": {
        "type": "Randomized, double-blind, placebo-controlled",
        "population": "FCS patients",
        "primary_endpoint": "Percent change from baseline in fasting TG at Week 10"
      },
      "results": {
        "tg_reduction": "-80%",
        "pancreatitis_risk_reduction": "83%",
        "interpretation": "Best-in-class efficacy; supported FDA approval"
      },
      "source": {
        "id": "arwr_thesis_2026",
        "verified": true
      }
    },
    "shasta2_phase2": {
      "trial_name": "SHASTA-2",
      "nct_id": "NCT04720534",
      "design": {
        "type": "Randomized, double-blind, placebo-controlled, dose-ranging",
        "population": "Patients with severe hypertriglyceridemia"
      },
      "results": {
        "tg_reduction_q12w": "-77%",
        "interpretation": "Supports quarterly dosing in broader sHTG population"
      },
      "source": {
        "id": "arwr_thesis_2026",
        "verified": true
      }
    },
    "ongoing_trials": [
      {
        "trial_name": "SHASTA-3",
        "nct_id": "NCT06347003",
        "phase": "Phase 3",
        "indication": "Severe Hypertriglyceridemia",
        "status": "Active, not recruiting",
        "data_expected": "2026"
      },
      {
        "trial_name": "SHASTA-4",
        "nct_id": "NCT06347016",
        "phase": "Phase 3",
        "indication": "Severe Hypertriglyceridemia",
        "status": "Active, not recruiting",
        "data_expected": "2026"
      },
      {
        "trial_name": "SHASTA-5",
        "nct_id": "NCT06880770",
        "phase": "Phase 3",
        "indication": "Severe Hypertriglyceridemia",
        "status": "Recruiting",
        "data_expected": "2026"
      },
      {
        "trial_name": "SHASTA-10",
        "nct_id": "NCT06822790",
        "phase": "Phase 3",
        "indication": "Severe Hypertriglyceridemia",
        "status": "Recruiting"
      },
      {
        "trial_name": "MUIR-3",
        "nct_id": "NCT06347133",
        "phase": "Phase 3",
        "indication": "Mixed Hyperlipidemia",
        "status": "Active, not recruiting"
      }
    ]
  },
  "regulatory_status": {
    "fda_approval": {
      "brand_name": "REDEMPLO",
      "approval_date": "2025-11-18",
      "indication": "Adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS)"
    },
    "pending_approvals": [
      {
        "indication": "Severe Hypertriglyceridemia",
        "status": "NDA filed",
        "pdufa_date": "H1 2026"
      }
    ]
  },
  "investment_analysis": {
    "bull_case": [
      {
        "point": "First-in-class RNAi for APOC3 with best-in-class 80% TG reduction",
        "evidence": "PALISADE Phase 3: -80% TG, 83% pancreatitis risk reduction",
        "confidence": "High - FDA approved"
      },
      {
        "point": "sHTG represents 10x larger market opportunity",
        "evidence": "~500K US patients vs ~3K for FCS",
        "confidence": "High - if trials succeed"
      },
      {
        "point": "Amgen partnership provides experienced CV sales force",
        "evidence": "Amgen has established cardiometabolic commercial infrastructure",
        "confidence": "High"
      },
      {
        "point": "Durable quarterly dosing improves compliance",
        "evidence": "Q12W dosing vs weekly for volanesorsen",
        "confidence": "High"
      }
    ],
    "bear_case": [
      {
        "point": "FCS is a tiny orphan market",
        "evidence": "~3,000 US patients limits near-term revenue",
        "counter_argument": "sHTG is the real commercial opportunity"
      },
      {
        "point": "Competition from olezarsen (Ionis)",
        "evidence": "Tryngolza approved Dec 2024 for FCS",
        "counter_argument": "Plozasiran has higher TG reduction (80% vs 60%)"
      },
      {
        "point": "Amgen controls commercialization",
        "evidence": "Majority economics flow to partner",
        "counter_argument": "Royalties still meaningful on multi-billion market"
      },
      {
        "point": "No CV outcomes data yet",
        "evidence": "TG reduction is surrogate, not hard endpoint",
        "counter_argument": "Genetic validation of APOC3 LoF and CV risk"
      }
    ],
    "key_debates": [
      {
        "question": "Will Phase 3 sHTG trials succeed?",
        "bull_view": "Phase 2 data strong (-77%), mechanism validated",
        "bear_view": "Larger trials may show safety signals or less efficacy",
        "what_resolves_it": "SHASTA-3/4/5 data in 2026"
      }
    ]
  },
  "competitive_landscape": [
    {
      "competitor": "Volanesorsen (Waylivra)",
      "company": "Ionis/Sobi",
      "mechanism": "ASO targeting APOC3",
      "stage": "Approved (EU only)",
      "efficacy": "77% TG reduction",
      "differentiation": "Plozasiran has better safety (no platelet issues), less frequent dosing (quarterly vs weekly)"
    },
    {
      "competitor": "Olezarsen (Tryngolza)",
      "company": "Ionis",
      "mechanism": "GalNAc-ASO targeting APOC3",
      "stage": "Approved (US, Dec 2024)",
      "efficacy": "~60% TG reduction",
      "differentiation": "Both quarterly dosing. Plozasiran shows higher TG reduction (80% vs 60%). Commercial competition ongoing."
    }
  ],
  "catalysts": [
    {
      "event": "sHTG PDUFA decision",
      "timing": "H1 2026",
      "importance": "Critical",
      "what_to_watch": "Approval for larger sHTG market"
    },
    {
      "event": "SHASTA-3 topline data",
      "timing": "2026",
      "importance": "High",
      "what_to_watch": "TG reduction in sHTG population"
    },
    {
      "event": "SHASTA-4 topline data",
      "timing": "2026",
      "importance": "High",
      "what_to_watch": "TG reduction in sHTG population"
    }
  ],
  "sources": [
    {
      "id": "arwr_thesis_2026",
      "title": "ARWR Investment Thesis",
      "type": "Internal Analysis",
      "date": "2026-02-02"
    },
    {
      "id": "fda_approval",
      "title": "FDA Approval Letter - REDEMPLO",
      "type": "Regulatory",
      "date": "2025-11-18",
      "url": "https://api.fda.gov/drug/drugsfda.json"
    },
    {
      "id": "clinicaltrials",
      "title": "ClinicalTrials.gov",
      "type": "Clinical Trial Registry",
      "url": "https://clinicaltrials.gov/api/v2/studies"
    }
  ]
}
